Kiromic BioPharma: AI-Driven Immuno-Oncology Therapy Development
Mar. 26, 2021
Kiromic BioPharma (Nasdaq: KRBP) is revolutionizing next-generation allogenic CAR therapies for solid tumors. The Company’s proprietary target discovery engine, Diamond uses AI and a proprietary neural network to identify development targets, dramatically compressing man years and billions of drug development dollars required to develop new live drugs. Without Kiromic's Diamond, the management of all the data required to solve the Target Identification puzzle is both challenging and inefficient. The Company is also developing its novel gene-editing system (ABBIE) to deliver its product candidates. ABBIE allows for insertion of the genome template into the T cells so that they could express the CAR protein and other accessory proteins while possibly eliminating unwanted inhibitory proteins and carries a lower mutagenesis risk vs. classic double-cut gene edits.
